Pacira BioSciences, Inc. (PCRX) stock
PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)
Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –
Pacira BioSciences cash
Cash and short-term investments held at the end of each period.
Pacira BioSciences's cash was $251.03M at Jun 30, 2026. For fiscal 2025 it was $238.42M, down 50.8% from the year before. Over ten years it grew 4.3% a year on average. The highest annual figure on record is $656.41M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $238.42M | -50.8% |
| FY2024 | Dec 31, 2024 | $484.62M | +74.0% |
| FY2023 | Dec 31, 2023 | $278.58M | -3.5% |
| FY2022 | Dec 31, 2022 | $288.65M | -56.0% |
| FY2021 | Dec 31, 2021 | $656.41M | +25.8% |
| FY2020 | Dec 31, 2020 | $521.66M | +78.7% |
| FY2019 | Dec 31, 2019 | $291.95M | -23.9% |
| FY2018 | Dec 31, 2018 | $383.45M | +23.2% |
| FY2017 | Dec 31, 2017 | $311.35M | +80.4% |
| FY2016 | Dec 31, 2016 | $172.60M | +10.6% |
| FY2015 | Dec 31, 2015 | $156.11M | -0.4% |
| FY2014 | Dec 31, 2014 | $156.66M | +117.1% |
| FY2013 | Dec 31, 2013 | $72.15M | +66.1% |
| FY2012 | Dec 31, 2012 | $43.44M | -43.0% |
| FY2011 | Dec 31, 2011 | $76.15M | +191.4% |
| FY2010 | Dec 31, 2010 | $26.13M | +269.3% |
| FY2009 | Dec 31, 2009 | $7.08M | -42.9% |
| FY2008 | Dec 31, 2008 | $12.39M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $251.03M | -43.7% |
| Q1 FY2026 | Mar 31, 2026 | $202.18M | -59.0% |
| Q4 FY2025 | Dec 31, 2025 | $238.42M | -50.8% |
| Q3 FY2025 | Sep 30, 2025 | $246.33M | -45.7% |
| Q2 FY2025 | Jun 30, 2025 | $445.86M | +10.3% |
| Q1 FY2025 | Mar 31, 2025 | $493.63M | +51.5% |
| Q4 FY2024 | Dec 31, 2024 | $484.62M | +74.0% |
| Q3 FY2024 | Sep 30, 2024 | $453.81M | +93.0% |
| Q2 FY2024 | Jun 30, 2024 | $404.23M | +83.1% |
| Q1 FY2024 | Mar 31, 2024 | $325.89M | +87.3% |
| Q4 FY2023 | Dec 31, 2023 | $278.58M | -3.5% |
| Q3 FY2023 | Sep 30, 2023 | $235.19M | -28.5% |
| Q2 FY2023 | Jun 30, 2023 | $220.77M | -30.2% |
| Q1 FY2023 | Mar 31, 2023 | $174.00M | -61.5% |
| Q4 FY2022 | Dec 31, 2022 | $288.65M | -56.0% |
| Q3 FY2022 | Sep 30, 2022 | $328.73M | -52.6% |
| Q2 FY2022 | Jun 30, 2022 | $316.39M | -51.1% |
| Q1 FY2022 | Mar 31, 2022 | $452.19M | -23.4% |
| Q4 FY2021 | Dec 31, 2021 | $656.41M | +25.8% |
| Q3 FY2021 | Sep 30, 2021 | $693.86M | +30.4% |
| Q2 FY2021 | Jun 30, 2021 | $646.60M | +97.9% |
| Q1 FY2021 | Mar 31, 2021 | $590.06M | +85.3% |
| Q4 FY2020 | Dec 31, 2020 | $521.66M | +78.7% |
| Q3 FY2020 | Sep 30, 2020 | $532.13M | +100.3% |
| Q2 FY2020 | Jun 30, 2020 | $326.79M | +11.8% |
| Q1 FY2020 | Mar 31, 2020 | $318.46M | -22.8% |
| Q4 FY2019 | Dec 31, 2019 | $291.95M | -23.9% |
| Q3 FY2019 | Sep 30, 2019 | $265.64M | -31.3% |
| Q2 FY2019 | Jun 30, 2019 | $292.24M | -21.3% |
| Q1 FY2019 | Mar 31, 2019 | $412.44M | +21.4% |
| Q4 FY2018 | Dec 31, 2018 | $383.45M | +23.2% |
| Q3 FY2018 | Sep 30, 2018 | $386.41M | +31.4% |
| Q2 FY2018 | Jun 30, 2018 | $371.32M | -2.9% |
| Q1 FY2018 | Mar 31, 2018 | $339.79M | -11.4% |
| Q4 FY2017 | Dec 31, 2017 | $311.35M | +80.4% |
| Q3 FY2017 | Sep 30, 2017 | $294.08M | +82.5% |
| Q2 FY2017 | Jun 30, 2017 | $382.44M | – |
| Q1 FY2017 | Mar 31, 2017 | $383.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $172.60M | – |
| Q3 FY2016 | Sep 30, 2016 | $161.13M | – |
See a number that looks wrong?